NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Voyager Therapeutics Inc (NASDAQ: VYGR)

 
VYGR Technical Analysis
5
As on 16th May 2025 VYGR STOCK Price closed @ 3.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.91 & Strong Sell for SHORT-TERM with Stoploss of 7.90 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

VYGRSTOCK Price

Open 3.28 Change Price %
High 3.36 1 Day 0.02 0.61
Low 3.19 1 Week 0.02 0.61
Close 3.30 1 Month 0.19 6.11
Volume 362754 1 Year -3.73 -53.06
52 Week High 10.84 | 52 Week Low 2.85
 
NASDAQ USA Most Active Stocks
AFMD 0.28 211.11%
AMRS 0.14 100.00%
HCTI 0.01 -75.00%
BON 0.06 20.00%
PLUG 0.77 10.00%
NVDA 135.40 0.42%
AGMH 0.07 16.67%
GNLN 0.01 0.00%
LCID 2.84 5.58%
LMDX 0.02 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
AFMD 0.28 211.11%
NDRAW 0.03 200.00%
INZY 3.95 178.17%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
BCAC 22.71 125.30%
 
NASDAQ USA Top Losers Stocks
CTHR 0.02 -98.00%
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
TBIO 0.01 -83.33%
NBSTU 2.00 -82.44%
ZWZZT 10.00 -75.50%
HCTI 0.01 -75.00%
SRAX 0.10 -73.68%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
 
 
VYGR
Daily Charts
VYGR
Intraday Charts
Whats New @
Bazaartrend
VYGR
Free Analysis
 
VYGR Important Levels Intraday
RESISTANCE3.63
RESISTANCE3.52
RESISTANCE3.46
RESISTANCE3.39
SUPPORT3.21
SUPPORT3.14
SUPPORT3.08
SUPPORT2.97
 
VYGR Forecast May 2025
4th UP Forecast12.38
3rd UP Forecast9.47
2nd UP Forecast7.67
1st UP Forecast5.87
1st DOWN Forecast0.73
2nd DOWN Forecast-1.07
3rd DOWN Forecast-2.87
4th DOWN Forecast-5.78
 
VYGR Weekly Forecast
4th UP Forecast4.98
3rd UP Forecast4.44
2nd UP Forecast4.11
1st UP Forecast3.77
1st DOWN Forecast2.83
2nd DOWN Forecast2.49
3rd DOWN Forecast2.16
4th DOWN Forecast1.62
 
VYGR Forecast2025
4th UP Forecast20.59
3rd UP Forecast15.04
2nd UP Forecast11.62
1st UP Forecast8.19
1st DOWN Forecast-1.59
2nd DOWN Forecast-5.02
3rd DOWN Forecast-8.44
4th DOWN Forecast-13.99
 
 
VYGR Other Details
Segment EQ
Market Capital 139603008.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
VYGR Address
VYGR
 
VYGR Latest News
 
Your Comments and Response on Voyager Therapeutics Inc
 
VYGR Business Profile
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 75 Sidney Street, Cambridge, MA, United States, 02139
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service